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EDITORIAL REVIEW
Atrial natriuretic factor: Structure and functional properties
In 1964 Jamieson and Palade [1] published their study on the
morphological characterization of specific atrial granules, con-
cluding that atrial muscle fibers 'form and store a population of
granules presumably secretory in nature." At that time, it had
already been postulated that the atria were involved in extracel-
lular volume regulation [2] and, working along different lines of
evidence, some investigators were searching for a putative
natriuretic hormone [3]. It is therefore surprising that the
presence of atrial secretory granules did not command immedi-
ate attention as a possible source of a natriuretic substance.
More than 15 years elapsed before De Bold et al [4] reported the
decisive experiment showing that the atria of mammals indeed
contain a natriuretic factor. In this experiment it was found that
intravenous bolus administration of crude atrial but not ven-
tricular extract leads to a brisk natriuresis, diuresis, and
kaliuresis of very rapid onset (1 to 2 mm) and relatively short
duration (10 to 20 mm) [4]. The peak sodium excretion reached
as much as 30- to 40-fold basal levels, a magnitude of action
which immediately situated atrial natriuretic factor (ANF) as
the most powerful endogenous natriuretic substance described
to date. In addition, in the same study it was found that crude
atrial extract decreased blood pressure, the time course of this
effect closely following its natriuretic effect. Subsequently, the
atrium of several mammals, including humans, were shown to
contain the atrial natriuretic factor [5].
Since this discovery, progress on the identification and ac-
tions of the ANF has been remarkable. In a short span of 3
years, ANF was identified as a peptide or group of peptides
having direct vascular as well as natriuretic effects. These
peptides were purified, sequenced and synthesized, and the
entire sequence of an ANF precursor was established by
modern complementary DNA cloning techniques. Further-
more, the effects of pure and synthetic atrial peptides on renal
function, smooth muscle contractility, and the renin-angioten-
sin-aldosterone system have been characterized in broad terms.
The present non-inclusive short review is intended as a
critical appraisal of the pertinent literature on the chemical and
functional properties of ANF with special emphasis on the
latter. Some of the open questions and future perspectives will
also be considered. An opening cautionary note is pertinent.
Until there is direct and unequivocal evidence that ANF
circulates in blood and that its plasma concentration changes
with appropriate stimuli, ANF should not as yet be referred to
as a "natriuretic hormone." (See the note added in proof)
Chemical nature of ANF and its precursor: structure-activity
relationships
After the polypeptide nature of ANF was established [6—8],
several laboratories working independently obtained highly
purified preparations of atrial peptides with natriuretic and
vasoactive properties similar to those of crude atrial extract
[9—141. Soon thereafter several groups successfully purified rat
and human atrial peptides to homogeneity and determined their
amino acid sequences [15—22]. Based on the amino acid se-
quences, synthetic peptides were obtained, a development
which has had a considerable impact on further studies of the
chemical and functional nature of ANF. Instrumental in the
rapidity with which these tasks were accomplished was the
discovery of the vasoactive properties of ANF [23, 24] and the
development of bioassays using isolated intestinal and/or vas-
cular smooth muscle preparations [10, 12].
Figure 1 (bottom) shows the aminoacid sequence of several
atrial peptides. Various names were suggested for these pep-
tides, including cardionatrins [9], atriopeptins [16], orauriculins
[15]. The top of Figure 1 shows the entire sequence of the rat
ANF precursor (to be discussed below). It is apparent that all of
these structurally related peptides are derived from the C-
terminal portion of the precursor. The low molecular weight
peptide isolated from human atrium differs from the rat peptide
by only one amino acid, namely a methionine in place of an
isoleucine in position 134 of the rat precursor (see Fig. 1 and
[181).
Although all investigators have isolated a series of peptides
with natriuretic and smooth muscle relaxant activity, this does
not necessarily imply that several atrial peptides are produced
in vivo. Rather, it is possible and even likely that the multiplic-
ity of peptides results from in vitro artifacts. In this regard it
should be noted that the atria contain considerable quantities of
large molecular weight forms of ANF [13] which might be
subject to nonspecific proteolysis following extraction. At this
point, however, it is only conjectural which of the peptides is
naturally occurring. Since paired basic residues such as Arg'25-
Arg'26, and Arg151-Arg'52 are common sites of intracellular
proteolytic processing [25], two likely candidates for a mature
peptide produced in vivo would be either the 25-residue peptide
auriculin B [151 or the 24-residue peptide atriopeptin III [261. It
cannot be discounted, however, that less common processing
mechanisms might account for the longer [17] or shorter [15, 16]
forms isolated (see Fig. 1).
For the following discussion of structure-activity relation-
ships, refer to the sequences depicted in the bottom of Figure 1.
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There is consensus among all investigators in the field that the
disulfide bridge between Cys129 and Cys145 is essential for the
known biological activities of ANF [15, 161. Because
atriopeptins II and III as well as auriculins A and B have similar
natriuretic and smooth muscle relaxant activities as
cardionatrins I, it is apparent that neither the initial tetrapeptide
Ser-Leu-Arg-Arg nor the C-terminal Tyr are essential for the
known biological activities of ANF. On the other hand, removal
of the Phe-Arg dipeptide in the C-terminal portion (as in
atriopeptin I) markedly decreases, but does not completely
abolish, the natriuretic and vasorelaxant activities of ANF [22].
Interestingly, removal of this Phe-Arg dipeptide does not alter
the intestinal muscle (isolated chick rectum preparation) relax-
ant activity of ANF [16]. In our studies in the isolated perfused
rat kidney we were not able to separate the renal hemodynamic
and natriuretic effects of ANF [15, 27]. Thus, despite sugges-
tions to the contrary [16, 28], it is likely that the vasoactive and
natriuretic effects of ANF are inseparable [15, 27]. The mini-
mum length peptide tested to the present with full activity is
thus the 23-residue atriopeptin II. The term "full activity"
should be used advisedly, however, since the quantitative
determinations of biological activities of atrial peptides in all
studies reported to the present are, at best, imperfect.
Using synthetic oligonucleotide probes based on the struc-
tures of the peptides isolated, the predicted amino acid se-
quence of ANF precursors in rat and human atria have been
established by several laboratories using modern complemen-
tary DNA cloning techniques [29—33]. Figure 1 (top) depicts the
sequence of the ANF precursor from rat atria. It is particularly
gratifying that the sequences determined independently by
different laboratories are virtually identical. The entire pre-
cursor contains 152 amino acids with a hydrophobic signal
peptide of approximately 24 amino acids and a probable pre-
cursor of 126 amino acids. A single glycosylation site exists at
Fig. 1. Aminoacid sequences of rat atrial
natriuretic factor precursor (top) and of
atrial peptides isolated by several
laboratories (bottom). The sequence of
the rat atrial natriuretic factor precursor
comes from [29—31, 33]; Cardionatrin I,
[171; human ANP, [18]; auriculins A and
B, [151; atriopeptins I and II, [16];
atriopeptin III, [28]. The asterisk refers
to methionine substitution in place of
isoleucine in human ANP. (See text).
residues 87-89. Of particular interest are the arg-arg dipeptide
sequences boxed in Figure 1 since, as mentioned above, these
are common sites of cleavage for many prohormones. The
human ANF precursor differs considerably in the N-terminal
portion from that of the rat, and it also lacks the arg-arg
dipeptide just prior to the termination codon toward the 3' end
of the c-DNA [32]. The meaning of this species difference is not
clear at this point. It should be pointed out that other cleavage
points are possible (for example, pro-arg, ala-gly, leu-leu; see
Fig. 1) although these are less typical processing sites. What-
ever the actual site of cleavage and hence the natural occurring
peptide turns out to be, the elucidation of the ANF precursor
sequence represents a major step for directing future investiga-
tions on the chemical nature, structure-activity relationships,
and regulation of the production of ANF.
It has been reported that pig heart atria contain a larger
molecular weight polypeptide (cardiodilatin) which has
vasorelaxant activity and which is said to lack natriuretic
activity [34]. Partial sequence data of the N-terminal portion of
this polypeptide has been obtained [34]. Based on the con sider-
able homology between the pig atrial peptide with the rat and
human ANF precursor, two groups of investigators [29, 35]
proposed that it may be derived from the N-terminus of the
ANF precursor. According to these authors the ANF precursor
would contain two naturally occurring active peptides,
cardiodilatin and ANF. In our view the experimental evidence
does not justify such a conclusion. Indeed, the hypothesis is
based solely on the approximation of molecular weight by gel
filtration and on an undocumented lack of natriuretic activity.
Cardiodilatin could simply be the entire ANF precursor, which
is known to have weak biological activities. Thus, we believe
that before better evidence is available, cardiodilatin should not
be considered a natural protein which differs from ANF.
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Fig. 2. Effects of synthetic atrial natriuretic
factor (auriculin A) on renal functions in
anesthetized dogs. After control periods (C),
auriculin was administered as a prime (1.0
.tg/kg body wt) and a constant infusion (0.1
gImin/kg body wt) for 1 hr. After steady-state
experimental periods (E), the infusion was
stopped and recovery periods (R) were
performed. Results are mean SE (N = 5).
The figure is based on data from [381.
Abbreviations are: MBP, mean arterial blood
pressure; RPF, renal plasma flow; RVR, renal
vascular resistance; FF, filtration fraction;
GFR, glomerular filtration rate; V, urine flow
rate; Uosm, urine osmolality; CH2O, free water
clearance; FLNa, filtered load of Na; UNaV,
urinary Na excretion rate; FENa, fractional
excretion of Na; UKY, urinary K excretion
rate; , P< 0.05.
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Renal hemodynamic and natriuretic effects of ANF
The magnitude of the natriuretic effect of atrial extract and
specifically the increase in fractional fluid and sodium excretion
made it tempting to postulate that ANF directly inhibits tubular
reabsorption of sodium [4, 36, 371. This view persisted despite
inconclusive micropuncture and isolated epithelia experiments
(see below). On the other hand, studies in a functioning isolated
perfused rat kidney preparation showed that crude atrial extract
[24, 27] as well as pure and synthetic ANF [15, 27] have major
renal hemodynamic effects which explain the natriuresis, at
least in part. Recent studies in intact anesthetized or conscious
dogs and rats confirmed these findings [38—40].
Figure 2 depicts the overall effects of a continuous intra-
venous infusion of synthetic ANF (auriculin A) on renal hemo-
dynamic and excretory functions in anesthetized dogs [38]. As
shown, ANF decreases mean blood pressure and increases
GFR, urine flow rate, and sodium and potassium excretion. In
addition, ANF decreases urine osmolality without a significant
change in free water clearance. These effects were immediate,
sustained throughout 1 hr of infusion of ANF and, except for
urine osmolality, were almost completely reversible. During
steady-state experimental periods, ANF does not alter renal
plasma flow or total renal vascular resistance. Filtration frac-
tion (FF) increases markedly during the experimental periods
but remains elevated in the recovery periods at a time when
renal vascular resistance is above control levels. Administra-
tion of ANF to conscious dogs [38] or directly into the renal
artery of anesthetized dogs [39] produces the same overall
effects as those described above. Similar results were also
obtained recently in anesthetized or conscious rats [40].
The most striking renal hemodynamic action of ANF is its
ability to markedly increase GFR in a sustained and reversible
manner. This effect and the ANF-induced increase in filtration
fraction was first described in the isolated perfused rat kidney
[15, 24, 27]. The ANF-induced increase in GFR is not only
remarkable in view of its magnitude but also because it occurs
with a decreased mean blood pressure and an unchanged or
decreased renal plasma flow (RPF) (Fig. 2). The failure of some
studies to detect such a major change in GFR is most likely due
to the non-steady-state conditions which prevailed in these
experiments after bolus administration of crude atrial extract [4,
36]. Under this condition, the transient nature of the effect does
not allow precise measurements of GFR by the inulin clearance.
Even in these studies, however, inspection of the data reveals
that the ANF-induced increase in sodium excretion was but a
small fraction (10 to 20%) of the calculated increase in glomeru-
lar load. The extent to which the increase in GFR accounts for
the increase in sodium excretion will be considered in another
part of this review.
The mechanism by which ANF increases GFR has not yet
been elucidated. In functioning isolated perfused rat kidneys
there is a major increase in FF and a smaller but significant
increase in renal vascular resistance (RYR) [15, 27]. The
combination of these effects strongly suggests that ANF is a
preferential efferent vasoconstrictor and in this manner in-
creases glomerular capillary pressure and hence GFR. In intact
dogs (Fig. 2, [38, 39]) or rats [40] FF also increases. In our
hands, however, contrary to the increase in GFR and natriure-
sis, this is not an immediately reversible phenomenon (Fig. 2,
[38]). Thus, additional mechanistic explanations for the ANF-
induced increase in GFR are also possible. Among them,
redistribution of GFR to deeper nephrons and increase in
filtration coefficient (Kf) have been suggested [27, 38]. In regard
to the former, this seems not to be the case in intact rats since
it has been recently shown that the increase in single nephron
glomerular filtration rate (SNGFR) under continuous infusion of
synthetic ANF is proportional to the increase in total GFR [40].
An increase in Kf is an attractive possibility, but direct mea-
surements of single nephron hemodynamics are necessary to
elucidate the exact mechanism(s) of the ANF-induced increase
in GFR. Whatever the case, the increase in GFR is undoubtedly
the central hemodynamic effect of ANF on the kidney.
The effect of ANF on RVR and blood flow is complex and
sometimes apparently contradictory. Thus, depending on ex-
perimental conditions, ANF may decrease [15, 27, 28, 41, 42],
increase [15, 27], or have no effect [38—40] on renal vascular
resistance with the expected converse effects or lack of effect
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on renal plasma flow. These apparently contradictory results
are due to the influence of the initial levels of the renal vascular
resistance on the outcome of the response and to the transitory
nature of the renal vasorelaxant effect of ANF [15, 27, 38]. As
shown in Figure 3 in the functioning isolated rat kidney, ANF
increases RYR when the preparation is perfused in the absence
of vasoconstrictors (panel A), and markedly decreases RYR
when the preparation is initially vasoconstricted with endogen-
ously generated angiotensin II (panel B). Based on this finding
we postulated that ANF behaves as a functional antagonist to
vasoconstrictors with a small agonist (vasoconstrictive) action
[27]. ANF also decreases the RYR of isolated kidneys perfused
with other hormonal (norepinephrine, vasopressin) or non-
hormonal (ouabain, tetracaine) vasoconstrictors [27, 43]. In
pharmacological perfused kidney preparations which have a
very high initial RVR, ANF apparently only decreases the RVR
[28]. Initial studies in intact rats and rabbits showed an increase
in RBF immediately after the administration of crude atrial
extract [41, 42]. Further studies with continuous infusion of
synthetic ANF in intact dogs showed, however, that the in-
crease in RBF is very transitory. As shown in panel C of Figure
3, immediately after the start of the continuous intravenous
infusion of ANF, RBF does indeed increase very markedly but
the effect lasts only 1 to 2 mm. After the initial increase, RBF
returns to or even below control levels, while both GFR and
sodium excretion remains elevated [38]. A similar short lasting
relaxant effect was observed after direct administration of ANF
into the renal artery [39]. Thus, it is clear that ANF does not
increase RBF in normal intact animals in a sustained manner
and that the ANF-induced increase in GFR and sodium excre-
tion is not due to an increase in total RBF.
The reasons for the complex effect of ANF on RVR and RBF
in intact animals has not yet been elucidated. Although ANF
may be a primary renal vasodilator [28], it is possible that the
efferent vasoconstrictive effect observed in the isolated kidney
[15, 27] also occurs in intact animals resulting in no net change
in RVR. The vasoconstrictive effect does not necessarily result
from a direct action of ANF on the renal vasculature because it
is also possible that the peptide could release a slower acting
vasoconstrictor substance [38]. Consistent with this possibility
is the slower time-course of the vasoconstrictive response in
isolated kidneys as compared to its vasorelaxant response in
preconstricted isolated kidneys or in intact dogs (Fig. 3), and
the finding that RVR increases to above-control values in
auriculin-treated dogs during the recovery periods (Fig. 2 [38]).
It also cannot be ruled out that ANF induced a reflex renal
vasoconstriction in intact animals. In any event, it is clear that
ANF should not be generically considered a powerful renal
vasodilator as has been suggested [28]. In view of the strong
antagonistic effect to all vasoconstrictors tested to date [15, 27,
28, 43] it is possible, however, that ANF may be an important
renal vasodilator in states characterized by marked vasocon-
striction [28].
There is indirect evidence that ANF, in addition to increasing
GFR, increases inner medullary blood flow [27, 38, 42, 44].
Thus, bolus administration of crude atrial extract to rats in-
creases papillary flow as measured by the albumin distribution
method [42]. It also markedly decreases papillary urea concen-
tration [44] suggesting that the factor induces a wash-out of the
inner medulla. The effects of ANF in the isolated kidney may in
part be attributable to a redistribution of flow in this preparation
[27]. Finally, in intact dogs, constant infusion of ANF leads to
a decrease in urine osmolality without a change in free water
clearance (Fig. 2 [38]), a finding which is also consistent with a
wash-out of the inner medulla. It is possible that this wash-out
is due to the transient large increase in RBF [38, 39] rather than
to a sustained redistribution of flow to the inner medulla. If it
occurs, an increase in inner medullary blood flow and wash-out
of the papillary interstitium could be important contributing
factors to the ANF-induced natriuresis (see below). So far,
however, the evidence is too indirect and better methodology is
needed to study the putative effect of ANF on inner medullary
blood flow.
Despite initial suggestions to the contrary [36, 37], there is at
present no evidence for a direct sodium transport inhibitory
action of ANF. Early micropuncture and microcatheterization
studies indicated that, following intravenous administration of
crude atrial extract, there was no inhibition of tubular reabsorp-
conscious dogC
360 r
240 1-
120 ______0
f_Auriculin infusion
Fig. 3. Effect of synthetic atrial natriuretic factor (auriculin) on
renal vascular resistance (RVR) in three experimental
conditions. In isolated rat kidneys perfused in the absence of
vasoconstrictors, auriculin increases perfusion pressure (PP)
and RVR (panel A). In isolated rat kidneys preconstricted by
adding renin substrate to the perfusate (generation of
angiotensin II), auriculin decreases PP and the RVR (panel B).
In conscious dog, constant infusion of auriculin leads to a very
transient increase in renal blood flow (RBF) and then RBF and
RVR return to control levels. (See text and 115, 27, 38].)
1 mm
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tion in superficial nephron segments up to the distal tubule [36,
37]. It was then postulated that ANF acts on more distal
portions of the nephron, that is, cortical or medullary collecting
ducts [36, 37]. The non-steady-state conditions which prevailed
in these early studies made it difficult to assess the data. A more
recent micropuncture study in rats was performed using con-
stant infusion of synthetic ANF [401; measurements of overall
organ function, SNGFR, and tubular reabsorption were per-
formed in steady-state conditions. This study demonstrates that
ANF does not inhibit tubular reabsorption in superficial proxi-
mal tubules and Henle's loops. In addition, the data also show
that SNGFR increases in proportion to the increase in total
GFR and that there is an increase in tubular reabsorption
consistent with the increase in load to proximal tubules and
Henle's loop. The authors conclude that the increase in GFR in
these experiments may account entirely for the ANF-induced
natriuresis [40].
Attempts to demonstrate an effect of crude atrial extract, as
well as pure or synthetic peptide on transport properties of
isolated perfused nephron segments or isolated epithelia prepa-
rations have been negative. To our knowledge, however, there
are only two published reports which show that crude atrial
extract does not inhibit sodium transport in the toad bladder
[45] or chloride transport in frog cornea [46]. Unpublished work
from our Department of Physiology did not detect an effect of
crude atrial extract or synthetic ANF on fluid reabsorption in
isolated perfused proximal convoluted tubules of the rabbit (H.
C. Park, personal communication), on sodium transport in
isolated perfused cortical collecting ducts of the rabbit (G.
Frindt, personal communication), or on short-circuit current in
the toad bladder (L. Palmer, personal communication). Despite
all of these negative data, a direct tubular effect cannot be
completely eliminated. Thus, it is possible that ANF inhibits
sodium transport in papillary collecting ducts [36]. It should be
pointed out, however, that neither the magnitude of the natri-
uresis nor the increase in fractional excretion of fluid and
electrolytes are solid enough arguments to support the hypoth-
esis that ANF directly inhibits tubular reabsorption. It cannot
be overemphasized that even small changes in GFR may lead to
changes in filtered loads which are much higher than the
observed changes in urinary excretion. Therefore, putative
tubular effects of ANF cannot be studied in whole organ
experiments.
In view of the major effect of ANF on GFR and its lack of a
demonstrable direct tubular effect, the question arises as to
whether the ANF-induced increase in glomerular load could
fully explain the observed degree of natriuresis. Unfortunately,
the present state of knowledge of renal function does not allow
an unequivocal answer to this question. Increasing GFR by
other maneuvers (for example, infusion of glycine or glucagon)
leads to similar if not greater increases in absolute and frac-
tional sodium excretion as those observed after the administra-
tion of ANF [47]. It could be argued, however, that these
maneuvers disrupt glomerulotubular balance by either altering
peritubular physical forces or even directly inhibiting tubular
reabsorption of sodium. In fact, it is not known if perfect
glomerulotubular balance is ever maintained when GFR in-
creases to the extent observed after the administration of ANF,
or why glomerulotubular balance would be disrupted under
these conditions. In our view, however, the increase in GFR
alone is unlikely to account entirely for the magnitude of the
natriuresis. As previously noted, we believe that the ANF-
induced increase in sodium excretion is due to an increase in
glomerular load into a washed-out inner medullary interstitium
(see discussion in [27, 38]).
Effects of ANF on smooth muscle: possible mechanisms of
action
The initial reports showing that atrial extract has major
effects on the renal vasculature of the isolated kidney [24] and
counteracts the effects of norepinephrine in the isolated aorta
[23] highlighted the importance of investigating its effects on
smooth muscle contractility. Indeed, ANF was found to be a
potent relaxant in preconstricted isolated large arteries, vascu-
lar beds [10, 12, 15, 27, 28], or in intestinal smooth muscle
(isolated chick rectum preparation) precontracted with
carbachol [10].
The vasoactive properties of ANF differ markedly from those
postulated for another putative natriuretic hormone, the
ouabain-like substance(s) which is (are) apparently present in
plasma of volume-expanded animals [48, 49]. This putative
substance apparently inhibits Na-K-ATPase and in this manner
induces vasoconstriction [48, 49]. In this respect it is important
to note that ANF was shown not to inhibit Na-K-ATPase [45].
As far as sodium-volume homeostasis is concerned, the physi-
ological advantage of having a factor which induces both
natriuresis and vasorelaxation are obvious, particularly in view
of the selectivity of the vasorelaxant effect of ANF (see below).
The reactivity of different vascular structures to ANF varies
markedly. For example, the small agonist (vasoconstrictive)
effect of ANF in isolated kidneys perfused in the absence of
vasoconstrictors [15, 27] is apparently not present in other
isolated vascular preparations [12, 28]. Furthermore, precon-
stricted isolated aorta, renal artery, facial vein, and the renal
vascular bed preparations are far more sensitive to the
vasorelaxant effect of ANF than, for example, preparations of
coronary or hind-limb vascular beds [10, 12, 28, 50]. The reason
for this selectivity remains to be clarified.
Studies on the mechanism of action of ANF on smooth
muscle contractility are in their infancy. The functional antago-
nism of ANF toward vasoconstrictors is not due to a competi-
tive effect at the receptor level. Indeed, ANF counteracts
vasoconstriction induced by all hormonal and non-hormonal
agents tested to the present [10, 12, 15, 27, 28, 43]. It is of
interest, however, that ANF antagonizes angiotensin II-
induced contraction in the rabbit aorta more profoundly than
that produced by norepinephrine [12]. The inhibitory effect on
the latter may be overcome with high doses of the agonist while
this is not the case with angiotensin II [12]. The reason for this
phenomenon is unknown but the more pronounced "antago-
nism" to angiotensin II may explain the greater blood pressure
lowering effect of ANF in renin-dependent rather than in
renin-independent models of hypertension in the rat ([51], see
below).
The influence of extracellular [Ca] and calcium entry into
cells on the vasoactive properties of ANF has been investigated
in the isolated perfused rat kidney [27, 43]. In isolated kidneys
perfused in the absence of vasoconstrictors, the vasoconstric-
tive effect of ANF is almost completely abolished when perfus-
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ate [Cal is below 0.2 mivi or when verapamil is added to a
perfusate containing normal [Cal [27]. Thus, extracellular [Cal
and calcium entry into cells are essential for the vasoconstric-
tive effect of ANF in this preparation. On the other hand, the
vasorelaxant effect of ANF in isolated kidneys perfused in the
presence of vasoconstrictors is at least partially independent of
extracellular [Ca]. Indeed, the transient contraction obtained
with tetracaine in kidneys perfused in the absence of calcium
and presence of 1 mi EGTA is blocked by ANF [431. This
finding led us to postulate that the vasorelaxant effect of ANF is
at least partly mediated by alterations in intracellular calcium
homeostasis rather than changes in calcium entry into cells [431.
In this respect it is of interest that the ANF-induced increase in
cGMP in aortic tissue (see below) is also independent of
extracellular [Ca] [50]. The exact nature of the intracellular
events related to calcium homeostasis (for example, changes in
sarcoplasmic reticulum uptake or release of calcium) is yet
unexplained.
There is evidence that the vascular (and natriuretic) effects of
ANF are not mediated by prostaglandins [10, 521. The
vasorelaxant effect also does not depend on the integrity of the
endothelial lining of the vessels [50, 53]. There is now strong
evidence that ANF increases cGMP in plasma and in several
tissues, including vascular smooth muscle [50, 54]. This in-
crease is apparently due to an ANF-induced activation of
guanylate cyclase rather than to an inhibition of phosphodi-
esterases [50]. Thus, similarly to other vasorelaxants, it is
possible that cGMP is the secondary messenger of the ANF
vasorelaxant effect. Unfortunately, the exact role of cGMP on
smooth muscle contractility remains to be clarified. Finally, the
recent evidence of the presence of high affinity binding sites for
ANF in vascular smooth muscle which have a dissociation
constant consistent with the concentration of ANF that pro-
duces vasorelaxation [55] should provide a considerable im-
petus on the research to assist explanation of the mechanisms of
vascular smooth muscle action of ANF.
Effects of ANF on blood pressure and the renin-aldosterone
system
The natriuretic and blood pressure reducing effects of ANF
made it attractive for us to investigate its possible interaction
with other systems involved in the regulation of these param-
eters and its effects in experimental models of hypertension. As
shown in Figure 4, we observed that intravenous infusion of
ANF in anesthetized dogs markedly and reversibly decreases
renin secretion rate, plasma renin activity, and plasma aldos-
terone levels while plasma cortisol levels remain unchanged
[381. A similar depression on renin secretory rate was found by
another group of investigators which administered synthetic
ANF directly into the renal artery of anesthetized dogs [39].
The mechanism of the decrease in renin secretion cannot be
explained fully by these observations, but it is partly due to an
increase in sodium load to the macula densa generated by the
marked ANF-induced increase in GFR [38, 39]. The decrease in
plasma aldosterone levels may be due partly to the decrease in
plasma renin and hence angiotensin II. However, there is direct
evidence that crude atrial extract [561 as well as synthetic ANF
[57] markedly inhibits basal as well as angiotensin II, dibutyryl
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Fig. 4. Time course of the effect of synthetic atrial natriuretic factor
(auriculin) on plasma renin activity (PRA), renin secretory rate (RSR),
plasma aldosterone and cortisol levels in anesthetized dogs. Horizontal
hatched bars represent the period of infusion of auriculin (1.0 pg/kg
body wt prime, 0.1 g/min/kg body wt constant infusion). Results are
mean SE (N = 5). Auriculin reversibly decreased (*P < 0.05) PRA,
RSR, and plasma aldosterone levels. (Reproduced by permission from
[38])
cyclic AMP, ACTH, or potassium-stimulated aldosterone se-
cretion by isolated adrenal cells. Furthermore, it was shown
that this inhibition could be overcome by high doses of the
agonists [57]. The exact mechanism(s) by which ANF inhibits
aldosterone secretion in isolated adrenal cells is not known. The
available evidence suggests, however, that the inhibitory effect
occurs very early in the steroid biosynthetic pathway at a step
prior to cholesterol side chain cleavage [57].
The marked inhibitory effect of ANF on aldosterone and
renin secretion are obviously not responsible for the acute
natriuretic and hypotensive effects of the atrial peptides. It is
possible, however, that these effects of ANF may contribute to
a longer term modulation of sodium excretion and vascular
resistance.
Recent studies in our laboratory show that synthetic ANF
(auriculin A) exerts a marked blood pressure lowering effect in
renin-dependent, two-kidney, one-clip Goldblatt hypertensive
rats [51]. Far lesser reductions in blood pressure occur in
one-kidney, one-clip rats, a model characterized by a similar
degree of hypertension which is, however, not renin-dependent
[51]. Furthermore, prior sodium depletion which converts these
animals to a renin-dependent type of hypertension markedly
enhances the antihypertensive effect of auriculin. Although
other explanations are possible, these observations are consist-
ent with the findings in isolated aortic rings that ANF antago-
nizes the effects of angiotensin more profoundly than that of
other vasoconstrictors (see above, and [12, 51]).
Studies on the effects of ANF on the renin-angiotensin-
aldosterone system are at the beginning stages, but results thus
far suggest the possibility that ANF may modulate this system
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Fig. 5. Summary view of some main actions of administered atrial
natriurezic factor (ANF). Abbreviations are: Aldo, aldosterone; GFR,
glomerular filtration rate; FF, filtration fraction; RBF, renal blood flow;
R, vascular tone; TPR, total peripheral resistance; MBP, mean arterial
blood pressure; ECF, extracellular fluid volume. See the Summary and
Perspectives section for a description of the figure.
and in this manner further contribute to the regulation of
sodium-volume and blood pressure homeostasis.
Summary and perspectives
Since the discovery of ANF in 1981, remarkable advances
have been accomplished in the identification, purification, and
determination of the amino acid sequences of atrial natriuretic
and vasoactive peptides and their precursor. Nevertheless,
many questions remain unsolved including: (1) which of the
isolated peptides is (are) naturally ocurring; (2) what are the
stimuli for the biosynthesis of ANF precursor; (3) what are the
stimuli and mechanisms for the biochemical processing of the
ANF precursor; and (4) what are the stimuli and cellular
mechanisms of the secretion of atrial peptides. The rapid
advances of knowledge and technologies in molecular and cell
biology and physiology should make the answering of these
questions a fruitful undertaking for years to come.
Studies on the characterization of the effects of ANF have
lagged somewhat behind biochemical studies. Figure 5 presents
a summarized view of the main actions of ANF described to
date. ANF has a unique combination of properties increasing
GFR, natriuresis, diuresis, and kaliuresis without a sustained
increase in renal blood flow. In addition, ANF decreases blood
pressure and markedly inhibits renin and aldosterone secretion
and the plasma levels of these hormones. Finally, ANF has a
remarkable vascular smooth muscle activity, behaving as a
functional antagonist of vasoconstrictors. It is likely that these
are but a few of organic and cellular actions of ANF and that
many new discoveries will be forthcoming in the next years.
MBP The mechanisms of the actions of ANF are still very poorly
understood. Natriuresis, the central effect of ANF, is likely due
to its renal hemodynamic actions, particularly its ability to
increase GFR and possibly inner medullary blood flow. The
exact manner by which the increase in GFR is accomplished
remains to be elucidated. Studies on single nephron hemody-
namics, isolated glomeruli, and glomerular mesangial cells in
culture should provide better insights in this regard. The
multifaceted actions of ANF on renal function, smooth muscle
contractility, blood pressure, and hormone secretion open
exciting areas of research but at the same time impose serious
difficulties. It may be speculated that many of these actions
have as a common denominator a decrease in cytosolic calcium
ion activity brought about by an ANF-induced modulation of
calcium uptake or release from intracellular stores.
The results obtained to date already establish ANF as a
powerful investigative tool with which to study organic and
cellular functions involved in sodium-volume and blood pres-
sure homeostasis. These studies also open the possibility to
research ANF as a potential pharmacological tool to intervene
in disorders of renal hemodynamics, blood pressure, and extra-
cellular volume regulation. Although the physiological role of
ANF has not yet been established conclusively, the perspec-
tives in this novel field are indeed exciting and almost unlimited.
THOMAS MAACK
MARIA JOSE F. CAMARGO
H0LLIs D. KLEINERT
JOHN H. LARAGH
STEVEN A. ATLAS
New York, New York, USA
Note added in proof
After this article was completed, several investigators detected
ANF-like immunoreactivity in rat and human plasma (Lang et al, in Abs
17th Ann Mtg, Am Soc Physiol, 1984, p 162A; Tanaka et a!, Biochem
Biophys Res Commun 124:663, 1984; Gutkowska et al, Biochem
Biophys Res Commun 125:315, 1984; Atlas et a!, in Abs 67th Ann Mtg,
Endocrine Soc, 1985, in press). Although these data strongly suggest
that ANF is a circulating hormone, further studies are required to
characterize this ANF-immunoreactivity and to better define the factors
influencing its plasma levels.
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